Acute Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Acute Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2021-06-09Clinical Trial Update: Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 Mutations [Phase 2]
Phase 2 clinical trial investigating sodium stibogluconate in myelodysplastic syndromes and acute myeloid leukemia with specific p53 mutatio…
-
CLINICAL_TRIALS trial_result · 2021-06-08Clinical Trial Update: IA14 Induction in Young Acute Myeloid Leukemia [Phase 2]
Phase 2 clinical trial update for IA14 induction in young acute myeloid leukemia is reported, with the study status currently UNKNOWN.
-
CLINICAL_TRIALS trial_result · 2021-06-08Clinical Trial Update: Unrelated Umbilical Cord Blood (UBC)Transplantation [NA]
Clinical trial update for unrelated umbilical cord blood transplantation; the study is completed with results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-06-01Clinical Trial Update: Aza-Ven Followed by Reduced Toxicity Conditioning Regimen (MBF) as Salvage Therapy for Refractory AML. [Phase 2]
Phase 2 trial evaluating Aza-Ven followed by reduced toxicity conditioning regimen (MBF) as salvage therapy for refractory acute myeloid leu…
-
CLINICAL_TRIALS trial_result · 2021-05-24Clinical Trial Update: Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML). [Phase 1]
Phase 1 study evaluating alvocidib with cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia has completed with results p…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-05-19Clinical Trial Update: Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS [Phase 2]
Phase II trial update for DAC in relapsed/refractory and elderly patients with acute myeloid leukemia and myelodysplastic syndrome.
-
FDA approval · 2021-05-17FDA Approved: ONUREG — Supplemental Application (Celgene Corporation)
The FDA approved a supplemental application for ONUREG (azacitidine) from Celgene Corporation, expanding its labeling to include maintenance…
-
CLINICAL_TRIALS trial_result · 2021-05-13Clinical Trial Update: A Phase I-II Open Label Non-Randomized Study Using TL32711 for Patients With Acute Myelogenous Leukemia, Myelodysplastic Syndrome and Acute Lymphoblastic Leukemia [Phase 1, Phase 2]
Phase I-II open-label trial of TL32711 in acute myeloid leukemia, myelodysplastic syndrome, and acute lymphoblastic leukemia; study terminat…
-
CLINICAL_TRIALS trial_result · 2021-05-13Clinical Trial Update: Anti-CLL1 CAR T-cell Therapy in CLL1 Positive Relapsed/Refractory Acute Myeloid Leukemia (AML) [Phase 1, Phase 2]
Phase 1/2 trial of anti-CLL1 CAR T-cell therapy for relapsed/refractory AML; status not reported.
-
CLINICAL_TRIALS trial_result · 2021-05-11Clinical Trial Update: Aprepitant as Antiemetic Prophylaxis in Patients With Acute Myeloid Leukemia Undergoing Induction Chemotherapy [Phase 2]
Phase 2 trial evaluating aprepitant as antiemetic prophylaxis in patients with acute myeloid leukemia undergoing induction chemotherapy has …
-
CLINICAL_TRIALS trial_result · 2021-05-11Clinical Trial Update: Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML) [Phase 1, Phase 2]
Phase 1/2 trial assessing TAK-659 in adults with relapsed or refractory acute myeloid leukemia (AML) has been terminated; results were poste…
-
CLINICAL_TRIALS trial_result · 2021-05-05Clinical Trial Update: Randomised Study of Azacitidine Versus Azacitidine With Vorinostat in Patients With AML or High Risk MDS [Phase 2]
Phase 2 randomized trial comparing azacitidine alone versus azacitidine with vorinostat in patients with acute myeloid leukemia or high-risk…
-
CLINICAL_TRIALS trial_result · 2021-05-04Clinical Trial Update: DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2 [Phase 1, Phase 2]
Clinical trial update for DEPLETHINK (NKR-2) reporting Phase 1/Phase 2 results in AML and MDS; trial status completed.
-
CLINICAL_TRIALS trial_result · 2021-04-28Clinical Trial Update: The Use of Decitabine as Induction Therapy for Acute Myeloid Leukemia With Complex and/or Monosomal Karyotype [Phase 2]
Phase 2 trial update on using decitabine as induction therapy for acute myeloid leukemia with complex and/or monosomal karyotype.
-
CLINICAL_TRIALS withdrawal · 2021-04-27Clinical Trial Update: Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT [Phase 3]
Phase 3 randomized trial evaluating standard of care with or without atorvastatin for prevention of graft-versus-host disease in matched unr…
-
CLINICAL_TRIALS trial_result · 2021-04-26Clinical Trial Update: Vidaza and Valproic Acid Post Allogeneic Transplant for High Risk AML and MDS [Phase 2]
Phase 2 clinical trial evaluating Vidaza (azacitidine) and valproic acid after allogeneic transplant in high-risk AML and MDS.
-
CLINICAL_TRIALS trial_result · 2021-04-20Clinical Trial Update: MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy [Phase 1, Phase 2]
Phase 1/2 trial of MEK inhibitor 162 in relapsed/refractory acute myeloid leukemia with poor prognosis; the study terminated with posted res…
-
EMA withdrawal · 2021-04-16EMA Application withdrawn: Tibsovo (Ivosidenib) — Agios Netherlands B.V.
The EMA has withdrawn the applicant for Tibsovo (ivosidenib) by Agios Netherlands B.V. for acute myeloid leukemia.
-
CLINICAL_TRIALS trial_result · 2021-04-13Clinical Trial Update: Busulfan and Cyclophosphamide Followed By ALLO BMT [NA]
Clinical trial update for busulfan and cyclophosphamide followed by allogeneic stem cell transplant in acute leukemias; study is terminated …
-
CLINICAL_TRIALS trial_result · 2021-04-08Clinical Trial Update: Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible [Phase 2]
Phase 2 pilot trial of pazopanib in patients with relapsed/refractory AML or newly diagnosed where intensive treatment isn’t possible comple…
-
CLINICAL_TRIALS trial_result · 2021-04-01Clinical Trial Update: A Phase 2 Study of Venetoclax in Combination With Low-dose HHT, G-CSF, and AZA as First-line Treatment for Newly Diagnosed Elderly AML Patients Unfit for Intensive Chemotherapy [Phase 2]
Phase 2 study evaluating venetoclax with low-dose hypomethylating agent, G-CSF, and azacitidine as first-line treatment for newly diagnosed …
-
FDA approval · 2021-03-30FDA Approved: VYXEOS — Supplemental Application (Jazz Pharmaceuticals, Inc.)
The FDA approved a supplemental application for VYXEOS (daunorubicin and cytarabine liposome) from Jazz Pharmaceuticals, Inc.
-
CLINICAL_TRIALS trial_result · 2021-03-26Clinical Trial Update: A Phase 2 Trial to Evaluate the Efficacy and Safety of OCV-501 in Elderly Patients With Acute Myeloid Leukemia [Phase 2]
A Phase 2 trial assessing efficacy and safety of OCV-501 in elderly patients with Acute Myeloid Leukemia has completed and posted results.
-
CLINICAL_TRIALS trial_result · 2021-03-24Clinical Trial Update: Early Palliative Care for Patients With Haematological Malignancies [Phase 3]
Phase 3 clinical trial update on early palliative care for patients with hematologic malignancies including acute myeloid leukemia and myelo…
-
CLINICAL_TRIALS trial_result · 2021-03-22Clinical Trial Update: Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms [Phase 2]
Phase 2 trial evaluating early allogeneic hematopoietic cell transplantation for patients with relapsed or refractory high-grade myeloid neo…